Type of G-CSF regimen and pattern of use has also been associated with differential FN treatment outcomes in a Spanish population with non-myeloid tumours, where daily use of filgrastim for only 5–6 days may have impacted treatment benefit negatively in terms of FN prophylaxis [25]. This evidence concerns the gene CSF3 and myeloid neoplasm.